# Effect of Ebastine in Patients With Diarrhea Predominant Irritable Bowel Syndrome

> **NCT07114055** · PHASE2,PHASE3 · RECRUITING · sponsor: **Md. Hazrat Ali** · enrollment: 60 (estimated)

## Conditions studied

- Irritable Bowel Syndrome - Diarrhoea

## Interventions

- **DRUG:** ebastine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07114055
- **Lead sponsor:** Md. Hazrat Ali
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-15
- **Primary completion:** 2026-07
- **Final completion:** 2026-07
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2025-08-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07114055

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07114055, "Effect of Ebastine in Patients With Diarrhea Predominant Irritable Bowel Syndrome". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT07114055. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*